Metabolic syndrome and liver transplantation: A review and guide to management  by Watt, Kymberly D.S. & Charlton, Michael R.
Frontiers in Liver TransplantationMetabolic syndrome and liver transplantation: A review and guide
to management
Kymberly D.S. Watt, Michael R. Charlton*
Department of Gastroenterology and Hepatology, Mayo Clinic and Foundation, MN, USAMetabolic syndrome is common among liver transplant recipients abdominal girth, hypertension, hyperglycemia and dyslipidemia
before and after transplantation. The components of metabolic
syndrome are often exacerbated in the post-transplant period by
transplant speciﬁc factors, such as immunosuppression, and are
strongpredictors of patientmorbidity andmortality.Many aspects
of the metabolic syndrome are modiﬁable. Early recognition, pre-
vention and treatment of post-transplant hypertension, obesity,
dyslipidemia and diabetes may impact long-term post-transplant
survival. Further study into the prevention and management of
these issues in the transplant patient are needed.
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by Elsevier B.V. All rights reserved.Introduction
The global epidemic of obesity and the metabolic syndrome is
affecting almost every aspect of liver transplantation (LT), includ-
ing the type and incidence of post-operative complications.
Although the frequency of end-stage liver disease among patients
with non-alcoholic fatty liver disease (NAFLD), an important but
single manifestation of obesity and the metabolic syndrome, is
not known, the frequency of NAFLD as an indication for liver trans-
plantation has increased every year since 2001 and is currently the
fourth most common indication [1]. In contrast, the frequency of
HCV as an indication for liver transplantation peaked in 2002 at
28% in the USA and has declined every year since (http://
www.ustransplant.org/) (Fig. 1). It has been projected that NAFLD
will be the most common indication for liver transplantation in
the next 10–20 years [2]. Sequential improvements in the efﬁcacy
and tolerability of immunosuppression have reduced chronic
rejection to a minor cause of graft loss [3]. Indeed, hepatic etiolo-
gies are the basis of aminority of late post-LT deaths [3], increasing
the importance of non-hepatic causes.
Metabolic syndrome (MS), as deﬁned by the criteria of the
National Cholesterol Education Program Adult Treatment Panel
III (NCEP ATPIII, Table 1) [4,5], is a compilation of metabolic man-
ifestations of obesity, deﬁned by a combination of increasedJournal of Hepatology 20
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age-dependent increase to >40% in individuals over the age of
60 [6] and a linear increase in prevalence with increasing body
mass index (BMI) [6]. The close relationship of MS with overnu-
trition and obesity is demonstrated by the near absence of MS
in patients with BMI < 25 kg/m2. There is some variation in the
prevalence of MS with ethnicity, with higher prevalences among
Native, Hispanic and African American populations, particularly
women [7]. Although the presence of any of the four cardinal fea-
tures of metabolic syndrome in an individual is a risk factor for
cardiac morbidity, the presence of three or more is associated
with up to 50% greater risk of major coronary events [7–9]. Lakka
et al. reported a 4.26-fold relative risk for mortality due to heart
disease and a 1.77 relative risk for all-cause mortality in men
with the metabolic syndrome [10].
The prevalence of MS in patients with cirrhosis and end-stage
liver disease is not well established and may vary with the etiol-
ogy of their liver disease, with an increased prevalence reported
among patients with cryptogenic cirrhosis (29% prevalence of
MS in 134 patients with cryptogenic cirrhosis compared to 6%
in 81 cirrhotic patients of other etiologies) [11]. The low systemic
vascular resistance that is a hall mark of portal hypertension, and
the low lipid levels associated with chronic liver disease reduces
the frequency of criteria for metabolic syndrome in patients with
end-stage liver disease. Despite this, a case control study
observed that 24–47% of patients with cirrhosis were obese and
20–47% had diabetes, with some variability depending on the eti-
ology of the underlying disease [12].
Features of the metabolic syndrome increase in prevalence
following liver transplantation. The absolute prevalence of diabe-
tes rises from 15% prior to liver transplant to 30–40% after
transplantation, with hypertension similarly increasing from a
pre-transplant prevalence of 15% to 60–70% after transplanta-
tion [13–15]. Although uncommon prior to transplant, hyperlip-
idemia is seen in approximately 50–70% of patients after
transplant [14]. MS has been described in 44–58% of patients fol-
lowed >6 months after transplantation [15,16] and is associated
with increased cardiovascular and cerebrovascular events [15].
Cardiovascular disease is a cause of 19–42% of non-liver related
mortality after transplant [13,17,18]. Diabetes, hypertension
and renal insufﬁciency individually confer a 2-fold increased risk
of mortality after transplant and more speciﬁcally, for cardiovas-
cular death and liver related deaths [13], thus the impact of MS
on liver transplant recipients is substantial.10 vol. 53 j 199–206
0
5
10
15
20
25
30
35
‘02 ‘03 ‘04 ‘05 ‘06
LT for NASH/ CC
LT for NASH/50% CC
LT for HVC (not HCC)
Fig. 1. Temporal changes in the frequency of HCV infection and NAFLD as
indications for liver transplantation in the United States. NAFLD is projected to
become the most frequent indication before 2020.
Frontiers in Liver TransplantationThe impact of MS on liver transplantation can be observed not
only in recipients but also among potential liver donors. Many
organ donors die of the disease consequences due to MS, includ-
ing cerebral vascular accidents and cardiovascular disease, and
these atherosclerotic diseases can potentially affect the liver allo-
graft. The donor pool is undeniably reduced, however by obesity
and liver steatosis.Components of metabolic syndrome post-liver transplant
Obesity
The 2005 World Health Organization (WHO) global projections
indicate that the already staggering number of approximately
1.6 billion overweight and 400 million obese adults will increase
to 2.3 billion and 700 million, respectively, by 2015 (http://
www.who.int/mediacentre/factsheets/fs311/en/index.html). The
WHO categorizes obesity according to BMI (overweight = BMI
25–29.9 kg/m2, class I = BMI 30–34.9 kg/m2, class II = BMI 35–
39.9 kg/m2, class III = BMIP 40 kg/m2). The prevalence of class
III obesity quadrupled and BMIP 50 quintupled [19] between
1986 and 2000. An increased waist circumference (by ATP III def-
inition) was observed in 46% of non-diabetic patients that devel-
oped MS over a 5-year follow-up [20]. The International Diabetes
Federation [21] expands the waist circumference descriptor
based on ethnicity (South Asians, Chinese and South/Central
American (90 cm for men, and 80 cm for women), Japanese
(85 cm for men and 90 cm for women), and all others (94 cmTable 1. NCEP ATPIII criteria for metabolic syndrome.
P3 of the criteria
Impaired glucose tolerance Fasting plasma glucoseP100 mg/dl
(5.6 mmol/L)
Abdominal obesity Waist circumference
>102 cm (40 in) in men,
>88 cm (35 in) in women
Hypertriglyceridemia P150 mg/dl (1.7 mmol/L) or
drug treatment for high TG
Low levels of HDL <40 mg/dl (1 mmol/L) in men,
<50 mg/dl (1.3 mmol/L) in women or
drug treatment for low HDL
High blood pressure P130/85 mmHg or drug treatment
for hypertension
The International Diabetes Federation uses the same criteria but expands the
Waist circumference criteria based on ethnicity. South Asians, Chinese and South/
Central American (90 cm for men, and 80 cm for women), Japanese (85 cm for
men and 90 cm for women), and all others (94 cm for men, 80 cm for women).
200 Journal of Hepatology 201for men, 80 cm for women), appropriately categorizing more peo-
ple with metabolic syndrome [22]. Central adipose tissue (‘apple’
shaped individuals), typically manifest as increased abdominal
girth, is more metabolically active than peripheral adipose tissue
(‘pear’ shaped individuals) and confers a greater risk factor for
metabolic syndrome and cardiovascular disease [23–25].
The increasing average BMI of the population in general has
been mirrored by patients undergoing liver transplantation. Over
one-third of patients with end-stage liver disease are obese
[12,16]. Non-alcoholic steatohepatitis (NASH) related cirrhosis is
a leading indication for liver transplant and this disease burdenwill
increase as the prevalence of NASH is expected to continue to
increase over the coming years [2,1] (Fig. 1). Between 1990 and
2006, the proportion of LT recipients classiﬁed as obese increased
from15% in the early 1990s to just over 25% since 2002, an increase
in average recipientweight of approximately 1 kgperyear [26–28].
Many transplant centers had or have an upper limit of BMI,
above which it was thought to be a contraindication to liver
transplantation. This approach was largely a reﬂection of the con-
cern for worse peri-operative morbidity and mortality [29,30],
initially substantiated by an SRTR registry analysis reporting that
post-transplant mortality at 5 years was greater among recipients
with class II (body mass index (BMI)P 35 kg/m2) and class III
(BMIP 40 kg/m2) obesity than in non-obese recipients [31]. A
potentially important limitation of this analysis was an inability
to correct BMI for ascites. If recipients with greater amounts of
ascites are at increased risk for post-operative morbidity and
mortality, then the increased risk for post-operative morbidity
and mortality that was being reported to be associated with
higher BMI may, in fact, reﬂect the impact of ascites on post-
operative outcomes. Most other studies suggest that with higher
BMI, longer length of hospital stays and more frequent complica-
tions, such wound healing are more the issue than patient mor-
tality [32–36]. A large National Institutes of Health Liver
Transplant Database study in which BMI was corrected for asci-
tes, showed not only that carefully selected obese transplant
recipients (obese patients with normal pre-operative cardiovas-
cular evaluation) had similar graft and patient survival at 1 and
5 years, but that underlying ascites may be a more important fac-
tor in poor outcomes and needs to be taken into account when
interpreting the impact of BMI on post-transplant outcomes
[37]. The combination of high MELD scores and severe obesity
(BMI > 40) was reported in a recent United Network of Organ
Sharing (UNOS) database study to be associated with decreased
post-transplant survival [38].
Weight distribution, rather than absolute BMI, may be more
important in determining liver transplant candidacy and estima-
tion of post-transplant risk. Patients with a pear shaped body
habitus may have less risk of wound issues and potentially less
coincident cardiovascular disease than a similar BMI with an
apple shaped body habitus. It is well documented in the non-
transplant population that central intra-abdominal adipose tissue
is more atherogenic and poses a greater risk of cardiovascular
disease than peripheral adipose tissue [24,25]. As many pre liver
transplant patients suffer from ascites, abdominal girth is fre-
quently not an adequate measure of central obesity. Ultrasound,
CT or MRI imaging may be required to differentiate ascites ﬂuid
from adiposity, with CT and MRI being better to differentiate vis-
ceral adipose tissue from subcutaneous adipose tissue [25,39].
The prevalence of obesity among the donor population will be
similar to that of the general population and has a major impact0 vol. 53 j 199–206
Table 2. Transplant speciﬁc factors contributing to post transplant metabolic
syndrome.
Factor Metabolic consequences References
Surgical Denervation – increased insulin resistance
(diabetes)
[53]
Steroid Truncal fat distribution (obesity) [54,76]
" Gluconeogenesis,
; glucose utilization (diabetes)
; b-cell insulin production
Mineralocorticoid effect,
" SVR (hypertension)
Calcineurin
inhibitor
Tac > CYA: [55,74,86]
b-cell toxicity, insulin secretion
Induce insulin resistance (diabetes)
CYA > Tac:
Reduce cholesterol transport into bile and
Bind/occupy LDL receptor (hyperlipidemia)
Renal vasoconstriction (hypertension)
mTOR inhibitor May increase insulin response (; diabetes) [56,72]
May block b-cell proliferation (" diabetes)
" Adipose tissue lipase activity,
; Lipoprotein lipase activity (hyperlipidemia)
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on the donor organ availability and use, as donor organs with
>30% fat are not used for liver transplant [40]. Not only does this
affect the deceased donor pool, but also the living donor pool. The
impact of obesity on the living donor pool for an individual seek-
ing transplant for steatohepatitis may be even greater as obesity
clusters among friends and relatives of affected individuals [41].
Obesity is a common sequelae of liver transplantation
[26,27,42]. With few exceptions, patients that are overweight or
obese prior to transplant will remain overweight or obese after,
withone-third of patients of normal weight at the time of trans-
plant becoming obese post-transplant [16,26]. The potential
impact of this weight gain includes increased osteoarthritis, sleep
apnea and most notably, increased risk of diabetes and metabolic
syndrome and associated complications, including cardiovascular
disease, renal disease and non-alcoholic steatohepatitis in the
allograft, to name a few. It should be noted that increased body
mass can result in altered drug metabolism as well, increasing
the volume of distribution, resulting in lower serum levels of
lipophilic drugs. Drugs dosed on weight that are not lipophilic,
can cause increased toxicity as well. Obesity may also differen-
tially affect cytochrome P450 enzyme activity with cytochrome
P450 3A4 activity decreasing and that of cytochrome P450 2E1
increasing [43].
Management of weight gain after transplant is fraught with
the same difﬁculties as the general population. Only orlistat
(tetrahydrolipstatin), a reversible inhibitor of pancreatic lipase,
has been investigated in the post-transplant setting and appears
to be of limited efﬁcacy and may interfere with immunosuppres-
sion absorption [44]. Bariatric surgery prior to transplant is a dif-
ﬁcult proposition in patients with portal hypertension, but may
be an option in carefully selected patients [45]. If weight loss sur-
gery is to be performed pre-LT, thought should be given to sleeve
gastrectomy, which preserves access to the gastric fundus (for
management of variceal bleeding) and the biliary tree, preserves
relative absorptive capacity and may result in less adhesions in
the transplant ﬁeld. There is also a risk of hepatic decompensa-
tion due to exacerbation of steatohepatitis following bariatric
surgery. Bariatric procedures in patients after liver transplant
appear to be well tolerated (with only a few cases reported in
the literature) and successful, but require a reoperation which
can be complex and can impact (depending on the procedure)
future access to the biliary tree if biliary complications arise
[46]. Gastric bypass surgery can also profoundly affect intestinal
drug absorption. One case report of gastric banding performed at
the time of the liver transplant procedure was successful and well
tolerated in an otherwise uncomplicated transplant [47]. Cer-
tainly more study into the optimal timing of these procedures
is required. The role of bariatric surgery in the context of liver
transplantation continues to evolve.
Diabetes
Glucose intolerance is frequently encountered in cirrhotic
patients, with 60–80% glucose intolerant and 10–15% diabetic
[48]. This is largely due to a baseline profound peripheral resis-
tance, with reduced glycogen synthesis and impaired glucose oxi-
dation in addition to a reduced b-cell secretion compensation
[49]. Approximately 4–6% of these patients will have improved
insulin sensitivity after liver transplant. Many patients will either
remain diabetic or develop new onset diabetes (NOD) after liver
transplant, with 20–37% of transplant patients remaining diabeticJournal of Hepatology 201long-term after transplant [50,51]. The majority of NOD (80%)
develops within 1 month of transplant, whereas only 12% of
patients, in one study, developed sustained NOD after the ﬁrst
year of follow-up [51].
Pre-transplant diabetes and BMI are predictive of post-trans-
plant diabetes [16], whereas hepatitis C infection (HR 2.5,
p = 0.001) and methylprednisolone boluses (HR 1.09 per bolus,
p = 0.02) are independent risk factors for the development of
NOD [52]. The transplanted liver itself may contribute to the
increase in insulin resistance as denervation/vagotomy of the liver
during liver transplantation has been associated with increased
insulin resistance [53]. After a liver transplant, patients are on
medications that may impact and complicate insulin sensitivity.
Corticosteroids induce insulin resistance in a dose-dependent
manner by decreased b-cell insulin production, increased gluco-
neogenesis and decreased peripheral glucose utilization [54],
whereas calcineurin inhibitors (cyclosporine and tacrolimus) can
decrease insulin synthesisand secretion (pancreaticb-cell toxicity)
and/or induce insulin resistance and hyperinsulinemia (Table 2). A
Cochrane review of trials comparing cyclosporine and tacrolimus
in liver transplant conﬁrmed the increased association of tacroli-
mus with de novo insulin-requiring diabetes mellitus (RR 1.38,
95% CI 1.01–1.86) found in renal transplant patients [55]. Siroli-
mus, an mTOR inhibitor, may block b-cell proliferation, increasing
the risk for diabetes, but on the other hand it has been shown to
inhibit the mTOR induced down regulation of insulin signaling in
insulin responsive cells (Table 2) [56]. Thus, the effect of sirolimus
on diabetes post-transplant is not clear.
Diabetes can have signiﬁcant impact on graft survival. Diabe-
tes and insulin resistance after liver transplant increases liver
injury and results in worse outcomes in a subset of transplant
patients transplanted with hepatitis C [52,57]. The 5-year occur-
rence of advanced ﬁbrosis is increased in patients treated for dia-
betes mellitus (49%) when compared to patients with normal
insulin sensitivity (20%) (p = 0.01). In addition, post-transplant
NOD is signiﬁcantly associated with late onset hepatic artery
thrombosis, acute and chronic rejection [51,58]. The effects of
recurrent or de novo fatty liver disease are discussed later. Overall
patient morbidity [58] and mortality are greater in patients with0 vol. 53 j 199–206 201
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both pre- and post-transplant diabetes [13,51,59,60], even when
post-LT diabetes is transient [51].
Goals of treatment of post-LT diabetes should mirror those for
the general population, as there are no studies speciﬁc to the liver
transplant population, with a target glycosylated hemoglobin of
<7%, fasting blood sugar of 70–130 mg/dl (3.9–7.2 mmol/L), and
peak post-prandial glucose <180 mg/dl (10 mmol/L) [61]. Treat-
ment of post-LT diabetes is largely with insulin in the peri- and
early post-operative setting. As steroids are tapered, every effort
should be made to initiate lifestyle modiﬁcations (diet and phys-
ical exercise) and possibly convert to an oral hypoglycemic agent.
Most oral agents have not been studied in the post-LT setting.
Potential advantages and disadvantages are outlined in Table 3.
Weight gain and hypoglycemia are less common with biguanides
(metformin) than sulfonylureas or thiazolidinediones. Metformin
however, should not be used in the setting of renal failure due to
the risks of lactic acidosis. Thiazolidinediones are generally well
tolerated, and may temporarily improve features of post-LT
NAFLD [62,63], but are also adipogenic and may be associated
with hepato [64] and cardiotoxicity [65].
It must be remembered that diabetes in this patient popula-
tion has the same long-term risks as the general population (as
many of these patients were diabetic or insulin resistant prior
to transplant) and thus annual retinal exams, urinary protein
screening and foot care should be encouraged.
Dyslipidemia
Dyslipidemia is unusual in patients with cirrhosis but is common
among LT recipients, 45–69% of whom develop hyperlipidemia
[14,16,66,67]. Dyslipidemia is a major risk factor for post-trans-
plant cardiovascular-related morbidity and mortality [50].
Although tacrolimus may be associated with less severe and
lower frequencies of dyslipidemia than cyclosporine [68], both
agents are associated with hyperlipidemia (Table 2) [69]. Siroli-
mus is a potent hyperlipidemic agent [70], possibly by affecting
the insulin signaling pathway, increasing adipose tissue lipaseTable 3. Potential advantages and disadvantages of oral agents.
Oral hypoglycemic
agent
Metabolism Advantage/disadvantage
Second generation
sulfonylureas
Hepatic, highly
protein bound
Weight gain, hypoglycemia
Glipizide CYP2C9 may " CNI level
Glicazide ?
Glyburide weak inh CYP2C8, 3A4
Glimipiride CYP2C9
Biguanides Not protein
bound
Lactic acidosis – rare (in renal
insufﬁciency, liver disease or alcohol
abuse, or heart failure). GI side effects,
metallic taste
Metformin Not
metabolized
Meglitinides Hepatic Weight gain, hypoglycemia only with
renal insuff, CNI – may " Repaglinide
level, expensive
Repaglinide CYP2C8, 3A4
Nateglinide CYP2C9, 3A4
Thiazolidinediones
(TZD)
Hepatic, highly
protein bound
Weight gain, ﬂuid retention
Rosiglitazone CYP2C8 Cardiovascular risk (rosi > pio),
expensive. CNI may ; metabolism TZD,
?liver toxicity (unclear)
Pioglitazone CYP2C8, 3A4
Alpha-glucosidase
inhibitors
GI tract
bacteria
GI side effects,
less effective, expensive
Acarbose
202 Journal of Hepatology 201activity, and decreasing lipoprotein lipase activity, particularly
when used in combination with cyclosporine [71,72]. There is
similar evidence of a synergistic hyperlipidemic affect between
cyclosporine and everolimus [73]. The basis of the relatively pro-
lipidemic effects of cyclosporine are not known but may involve
inhibition of hepatic bile acid 26-hydroxylase, thereby decreasing
bile acid synthesis from cholesterol and reducing the subsequent
transport of cholesterol into bile and the intestine [74]. In addi-
tion cyclosporine binds to the low-density lipoprotein (LDL)–cho-
lesterol receptor, thereby increasing circulating levels of LDL–
cholesterol [50,75]. The observation that tacrolimus appears less
likely to cause hypercholesterolemia than cyclosporine, has led
several groups to propose conversion of liver transplant recipi-
ents to tacrolimus-based immunosuppressive therapy from
cyclosporine-based therapy in the setting of persistent hypercho-
lesterolemia, with some evidence of efﬁcacy [68]. Post-transplant
hyperlipidemia is generally resistant to dietary interventions.
Whether calcineurin inhibitor dosing in general should be mini-
mized in patients with post-transplant metabolic syndrome is
not known but there exists a good rationale for such an approach.
Corticosteroids are known to produce insulin resistance, truncal
fat deposition, hypertension and dyslipidemia. Steroid free
immunosuppression post-LT does not, however, reduce rates of
dyslipidemia [76]. Only a small minority of patients require
maintenance corticosteroids, which can and should be discontin-
ued well before the end of the ﬁrst post-operative year. In addi-
tion to lowered dosing and type of calcineurin inhibitor and
corticosteroid tapering, pharmacotherapy should be considered
in patients with persistent hyperlipidemia.
If cholesterol and triglyceride levels are both elevated HMG
CoA inhibitors (statins) are an appropriate ﬁrst line agent. Statins
have been used commonly in solid organ transplant recipients for
decades and are well tolerated [77]. Pravastatin is the most stud-
ied and used statin in post-transplant patients due to its metab-
olism not requiring the P450 enzyme system, but many of the
other statins (atorvastatin, simvastatin, lovastatin, cerivastatin
and ﬂuvastatin) are used frequently in transplant patients. A
review by Asberg et al. [78], suggested a small (but not clinically
relevant) reduction in cyclosporine levels during statin therapy.
Similar effects are seen with tacrolimus and statins [79].
Although there is no de rigueur basis for reducing doses of statins
in the post-transplant setting, low initial doses and titration with
careful follow-up should be considered. Simvastatin (40 mg/day),
atorvastatin (40 mg/day) or pravastatin (20 mg/day) are reason-
able starting doses for post-LT hypercholesterolemia. It is impor-
tant to remember that the effects of statin therapy are additive to
those of a controlled diet, e.g. a Mediterranean diet rich in omega
3 fatty acids, fruits, vegetables and dietary ﬁber.
Hypertriglyceridemia with normal cholesterol levels is also
common post-LT. Hypertriglyceridemia responds to ﬁsh oil
(omega 3) and may be the agent of ﬁrst choice since very few side
effects and drug interactions can be expected [80]. Fish oil has
also been shown to have anti-inﬂammatory and anti-proliferative
properties, as well as to improve hepatic steatosis [81]. A starting
dose of 1000 mg BID, increasing to a total of 4000 mg daily in
divided dosing is reasonable. Fish oil has not been shown to affect
cyclosporine (a highly lipophilic agent) levels signiﬁcantly [78],
and is not known to affect tacrolimus metabolism. Doses above
4000 mg can have antiplatelet effects and increase risk of bleed-
ing [82]. Some patients may experience an increase in LDL levels
on ﬁsh oil, thus follow-up lipid panels should be performed.0 vol. 53 j 199–206
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Alternative agents include the ﬁbric acid derivatives (gemﬁbrosil,
cloﬁbrate, fenoﬁbrate), which are generally well tolerated, but
have occasionally been associated with muscle injury, particu-
larly if used with statins. Fibrates are highly protein bound and
cytochrome P450 metabolized with some evidence of a mild
effect of increasing calcineurin inhibitor levels [78].
Ezetimide, an agent that inhibits the enterohepatic recircula-
tion of lipids and has minimal cytochrome P450 metabolism,
has been show to be well tolerated and effective when used in
combination with statin drugs in a small retrospective study of
liver transplant patients [83]. There is a theoretical concern of
hepatotoxicity for ezetimide, particularly when used with statins,
thus caution should be exercised until more data is available in
liver transplant recipients.
Hypertension
Hypertension affects a relative minority of patients prior to trans-
plant but has been reported in up to 70% of liver transplant recipi-
ents [13–15,67]. The usual criteria is a blood pressure over 140/90,
which generally occurs early post-transplant and tends to be sus-
tained over time. Steroid induced hypertension is generally sec-
ondary to mineralocorticoid effects but it also independently
increases SVR aswell as cardiac contractility (Table 2) [54]. Hyper-
tensionmayoccur at a somewhat lower frequencywith tacrolimus
than with cyclosporine and is associated with increased body
weight and renal insufﬁciency [84]. Sirolimus increases the risk
of hypertension when added to other calcineurin inhibitors [85].
Mechanisms for hypertension after transplant are thought to be
largely related to renal (and systemic) vasoconstriction, as well
as impaired GFR and sodium excretion (Table 2) [86].
Because of the contribution of renal arteriolar vasoconstric-
tion to post-LT hypertension, calcium channel blockers (amlodip-
ine, isradipine and felodipine) are often used as ﬁrst line agents.
Nifedipine is an inhibitor of intestinal cytochrome P450, predict-
ably increasing CNI levels with potential for CNI toxicity, and may
cause leg edema. Second line therapies include speciﬁc b blockers
(non-speciﬁc b blockers may reduce portal blood ﬂow), ACE
inhibitors, angiotensin receptor blockers and loop diuretics [87].
ACE inhibitors and angiotensin receptor blockers may exacerbate
CNI-induced hyperkalemia, but may also provide anti-ﬁbrotic
properties for patients at high risk of liver ﬁbrosis (e.g. recurrent
hepatitis C, or steatohepatitis), and possibly protect against calci-
neurin induced renal injury [88]. Thiazides and other diuretics
are problematic in transplant recipients due to potentiation of
electrolyte abnormalities. Blood pressures goals are not estab-
lished speciﬁcally for liver transplant patients but a goal of
<130/80 is suggested for all patients with diabetes, chronic renal
disease or known (or at risk of) cardiovascular disease, which
would encompass the majority of post-transplant patients [89].
Up to 30% of patients may require two or more antihypertensives
to achieve these goals [67].
Consequences of metabolic syndrome post-liver transplant
Cardiovascular disease
It is estimated that 27% of patients considered for liver transplan-
tation have unknown underlying coronary artery disease [90,91].
Most patients with signiﬁcant cardiovascular disease are not can-
didates for liver transplantation. Even in those with mild to mod-Journal of Hepatology 201erate asymptomatic coronary artery disease the frequency of
post-LT cardiovascular complications is high [90,92]. NAFLD,
deﬁned as a positive ultrasound diagnosis of fatty inﬁltration, is
highly predictive of coronary artery, carotid artery and peripheral
vascular disease, even in the absence of underlying diabetes [93].
Speciﬁc screening for central and peripheral vascular disease
should be considered in potential LT recipients with NAFLD.
Cardiovascular disease is a leading cause of morbidity and
mortality in LT patients. The 10-year probability for coronary
heart disease (using the Framingham risk score [94]) is higher
in LT recipients (11%) than the general population (7%) [67]. An
increased relative risk of ischemic cardiac events (3.07, CI 1.98–
4.53) and cardiovascular deaths (2.56, CI 1.52–4.05) has been
reported in LT recipients when compared to age and sex match
general population [17]. A large multicentered prospectively
obtained transplant database study showed the leading non-
hepatic causes of deaths are malignancy (29.5%), infection/sepsis
(25.1%), and cardiovascular disease (19.3%) [13]. This study also
demonstrated that diabetes, hypertension and renal failure are
signiﬁcant risk factors for long-term mortality and more speciﬁ-
cally, for cardiovascular death and liver related deaths post-LT.
Hyperlipidemia was not evaluated in this study.
Renal insufﬁciency
Renal injury after liver transplant is often thought to be calcineu-
rin inhibitor toxicity, but other causes exist and must be evalu-
ated for. Metabolic syndrome parameters are intricately linked
on many levels with renal function. Hypertension can be a cause
of or caused by renal failure, diabetes causes renal injury in the
general diabetic population, and has been shown to be a risk fac-
tor for the development of chronic renal insufﬁciency after liver
transplant [95].
NAFLD/fatty allograft disease
Prospective histological analyses of protocol transplant biopsies
reported 60% of transplant patients with NASH, 5% of recipients
with cholestatic disease, 15% of recipients with alcoholic disease,
and 15% of recipients with HCV developed steatosis grade 2 or
higher at 1 year post-transplant [96]. In this study >50% NASH
patients with recurrent fatty liver, developed overt recurrent
NASH within 2 years post-transplant. Contos et al. [97], showed
52% of patients transplanted with NASH or cryptogenic cirrhosis
developed steatosis within 2 years and the probability of steato-
sis at 5 years post-LT was 100% in comparison to 25% probability
observed in control groups matched for age and weight with pre-
LT diagnoses of PBC or alcoholic liver disease. Between 5% and
10% of patients undergoing liver transplantation for NASH have
recurrence that progresses to cirrhosis in long-term follow-up
[96], with graft failure reported in about half of patients with cir-
rhotic stage recurrence (i.e., long-term absolute NASH recur-
rence-associated graft loss rate of 2.5–5%). A more recent
retrospective analysis had similar overall ﬁndings but observed
no NASH recurrence-associated graft loss [98].
A single center retrospective report of transplant recipients
without prior fatty liver described de novo fatty liver in 20%,
and de novo NASH in 10% post-LT [99]. The use of angioten-
sin-converting enzyme inhibitors has been associated with a
reduced risk of developing post-LT NAFLD (odds ratio, 0.09; 95%
p = 0.042). A BMI increase >10% after transplant is associated with0 vol. 53 j 199–206 203
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a higher risk of developing post-LT NAFLD (odds ratio, 19.38;
p = 0.001).
Recurrent hepatitis C and metabolic syndrome
Metabolic syndrome was recently shown to be a risk factor for
histologic progression of recurrent hepatitis C [100]. Insulin resis-
tance and diabetes are intricately linked with hepatitis C and are
established risk factors for ﬁbrosis progression in patients with
hepatitis C with or without a liver transplant [57,100]. Insulin
resistance is associated with reduced viral clearance on antiviral
medications [101]. Hepatitis C recurrence in the allograft is also a
risk factor for the development of new onset diabetes [102],
which we also know to be a risk factor for ﬁbrosis progression
as previously discussed. Hepatitis C infection has multiple effects
on lipid metabolism with reduced serum lipid levels (potentially
reducing the risk of cardiovascular disease), but creates an imbal-
ance in intracellular lipid metabolism, thus increasing hepatic
steatosis [103]. Viral eradication in these patients reverses these
effects and has resulted in increased serum lipid levels [104],
which must be monitored for.
Immunosuppression and metabolic syndrome
Patients with metabolic syndrome following liver transplantation
have higher risks of developing a major vascular event, and
immunosuppression can also affect post-transplantation meta-
bolic syndrome. Corticosteroids are known to produce insulin
resistance, truncal fat deposition, hypertension and dyslipidemia.
In addition to increasing oxidative stress and lipid peroxidation,
calcineurin inhibitors in general cause hyperlipidemia, hyperten-
sion and renal injury. Tacrolimus may be toxic to b cells and sirol-
imus is a potent inducer of dyslipidemia. In lieu of randomized
studies to determine optimal immunosuppression, steroid avoid-
ance and minimization of calcineurin inhibition should be con-
sidered in recipients at risk of MS. There is increasing evidence
that steroid avoidance and/or minimization of calcineurin inhib-
itors are safe and, moreover, reduces the frequency of metabolic
complications post-LT [76].
Summary
Metabolic syndrome and its components are very common com-
plications in the post-transplant setting with substantial impact
on morbidity and mortality of these patients. Early recognition,
prevention and treatment of these conditions may impact long-
term survival after liver transplant. Further study into the man-
agement of these issues in the transplant patient are warranted
and urgently needed.Conﬂicts of interest
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